- Raw materials
- Psicose
Filters
Filter
Custom request?
Type
Production region
Qualifications
Country of origin
Psicose API Manufacturers & Suppliers
1 verified results
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Commercial-scale Suppliers
Producer
Produced in
China|
Audit Report:
Certifications:
MSDS
|
BSE/TSE|
ISO9001|
CoAAll certificates
MSDS
BSE/TSE
ISO9001
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Get full market intelligence report
€399,-
All Psicose data. Full access. Full negotiation power
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Psicose | CAS No: 23140-52-5 | GMP-certified suppliers
A medication that is an investigational monosaccharide under study for its potential effects on carbohydrate metabolism and metabolic health.
Therapeutic categories
CarbohydratesHexosesKetosesMonosaccharides
Generic name
Psicose
Molecule type
small molecule
CAS number
23140-52-5
DrugBank ID
DB15087
Approval status
Investigational drug
Product Snapshot
- Psicose is an oral small molecule formulation
- It is primarily investigated for metabolic disorder applications
- Psicose is currently in the investigational stage and not yet approved by major regulatory authorities
Clinical Overview
Psicose (CAS Number 23140-52-5) is a monosaccharide classified as a hexose and ketose carbohydrate. It is currently under clinical investigation, including evaluation in trial NCT02459834, known as the Fructose and Allulose Catalytic Effects (FACE) Trial. The clinical indication for Psicose has not been formally established, and the compound remains in the investigational stage without regulatory approval for therapeutic use.
To date, no specific data on the pharmacodynamics or detailed mechanism of action of Psicose are publicly available. As a rare sugar structurally related to other hexose sugars, its biological activity and metabolic pathways remain a subject of ongoing research. The compound’s classification as a monosaccharide suggests potential involvement in carbohydrate metabolism; however, the exact interactions with metabolic enzymes or receptors have not been elucidated.
Key absorption, distribution, metabolism, and excretion (ADME) characteristics for Psicose have not been fully characterized in clinical or preclinical studies. This gap includes limited information on bioavailability, metabolic stability, and elimination pathways, necessitating further investigation before definitive pharmacokinetic profiles can be defined.
Safety and toxicity profiles for Psicose have not been comprehensively reported. As with many investigational monosaccharides, careful scrutiny regarding gastrointestinal tolerance, metabolic effects, and systemic toxicity will be required as clinical data emerge. No notable branded products currently exist containing Psicose as an active pharmaceutical ingredient.
From a sourcing and quality perspective, procurement of Psicose as an API for investigational use demands strict adherence to specifications regarding purity, stereoisomeric composition, and absence of contaminants. Reliable manufacturers should provide detailed certificates of analysis and comply with current good manufacturing practices (cGMP) to ensure consistency and suitability for clinical development applications.
To date, no specific data on the pharmacodynamics or detailed mechanism of action of Psicose are publicly available. As a rare sugar structurally related to other hexose sugars, its biological activity and metabolic pathways remain a subject of ongoing research. The compound’s classification as a monosaccharide suggests potential involvement in carbohydrate metabolism; however, the exact interactions with metabolic enzymes or receptors have not been elucidated.
Key absorption, distribution, metabolism, and excretion (ADME) characteristics for Psicose have not been fully characterized in clinical or preclinical studies. This gap includes limited information on bioavailability, metabolic stability, and elimination pathways, necessitating further investigation before definitive pharmacokinetic profiles can be defined.
Safety and toxicity profiles for Psicose have not been comprehensively reported. As with many investigational monosaccharides, careful scrutiny regarding gastrointestinal tolerance, metabolic effects, and systemic toxicity will be required as clinical data emerge. No notable branded products currently exist containing Psicose as an active pharmaceutical ingredient.
From a sourcing and quality perspective, procurement of Psicose as an API for investigational use demands strict adherence to specifications regarding purity, stereoisomeric composition, and absence of contaminants. Reliable manufacturers should provide detailed certificates of analysis and comply with current good manufacturing practices (cGMP) to ensure consistency and suitability for clinical development applications.
Identification & chemistry
| Generic name | Psicose |
|---|---|
| Molecule type | Small molecule |
| CAS | 23140-52-5 |
| UNII | KRF88IOA7T |
| DrugBank ID | DB15087 |
Formulation & handling
- Psicose is a small molecule with high water solubility, suitable for oral formulation.
- Its low LogP (-3.3) indicates hydrophilic properties, affecting membrane permeability considerations.
- No specific peptide or biologic handling precautions are required; stability under standard conditions should be verified.
Regulatory status
Psicose API manufacturers & distributors
Compare qualified Psicose API suppliers worldwide. We currently have 1 companies offering Psicose API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Changzhou Comwin Fine Che... | Producer | China | China | BSE/TSE, CoA, ISO9001, MSDS | 235 products |
When sending a request, specify which Psicose API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Psicose API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
